Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANTONIO ANZUETO

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1053428128
CMS profile
183560
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$430,077.81

279 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $124,287.42 41
AstraZeneca Pharmaceuticals LP $106,116.92 94
GlaxoSmithKline, LLC. $95,155.66 59
Regeneron Healthcare Solutions, Inc. $49,245.52 32
Viatris Specialty LLC $30,577.83 32
Verona Pharma, Inc. $16,950.00 13
Abbott Laboratories $6,533.17 2
PFIZER INC. $1,000.00 1
AstraZeneca AB $104.05 3
AstraZeneca UK Limited $87.17 1
Merck Sharp & Dohme LLC $20.07 1

Page 4 of 6; records 151–200 of 279 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANTONIO ANZUETO

NPI 1053428128 · CMS profile ID 183560

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 279 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1053428128?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANTONIO ANZUETO, NPI 1053428128, CMS profile ID 183560. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 279 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053428128?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ANTONIO ANZUETO, NPI 1053428128, CMS profile ID 183560. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 279 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053428128?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ANTONIO ANZUETO, NPI 1053428128, CMS profile ID 183560, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 279 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1053428128?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

279 matching records · $430,077.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 279 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 279.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $5.1106/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190376869 CMS
Viatris Specialty LLC $1,080.3706/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238484023 CMS
Viatris Specialty LLC $209.1706/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238484445 CMS
Viatris Specialty LLC $43.4506/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238484453 CMS
Viatris Specialty LLC $173.5906/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238484455 CMS
Viatris Specialty LLC $4,333.0006/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238484459 CMS
Viatris Specialty LLC $53.6606/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238484701 CMS
Regeneron Healthcare Solutions, Inc. $24.7306/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212863618 CMS
Regeneron Healthcare Solutions, Inc. $4,153.0006/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212863620 CMS
Regeneron Healthcare Solutions, Inc. $7,928.0006/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212863622 CMS
Verona Pharma, Inc. $698.3706/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233754591 CMS
Verona Pharma, Inc. $6,000.0006/10/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1233754593 CMS
Verona Pharma, Inc. $335.2306/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233754603 CMS
GlaxoSmithKline, LLC. $0.4306/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190751166 CMS
GlaxoSmithKline, LLC. $1.4506/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190882810 CMS
GlaxoSmithKline, LLC. $2.1206/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191319095 CMS
GlaxoSmithKline, LLC. $3.4706/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191444712 CMS
GENZYME CORPORATION $7,928.0006/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233242575 CMS
GENZYME CORPORATION $495.4606/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233242577 CMS
GENZYME CORPORATION $12.1206/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233242579 CMS
GENZYME CORPORATION $83.0406/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233242581 CMS
GENZYME CORPORATION $6,418.0006/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233242583 CMS
GENZYME CORPORATION $100.0006/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233242593 CMS
GENZYME CORPORATION $124.6406/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233242595 CMS
Regeneron Healthcare Solutions, Inc. $288.3706/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212863616 CMS
Abbott Laboratories $2,700.0006/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1240564031 CMS
Regeneron Healthcare Solutions, Inc. $117.4206/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212863614 CMS
Verona Pharma, Inc. $124.5806/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233754577 CMS
Verona Pharma, Inc. $3,000.0006/04/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1233754579 CMS
Verona Pharma, Inc. $24.4406/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233754581 CMS
Verona Pharma, Inc. $160.4806/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233754583 CMS
Verona Pharma, Inc. $180.8606/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233754585 CMS
Verona Pharma, Inc. $4,200.0006/04/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1233754587 CMS
Verona Pharma, Inc. $253.7406/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233754599 CMS
Verona Pharma, Inc. $166.4006/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233754601 CMS
Regeneron Healthcare Solutions, Inc. $280.4805/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212863612 CMS
Regeneron Healthcare Solutions, Inc. $7,928.0005/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212863608 CMS
Regeneron Healthcare Solutions, Inc. $3,398.0005/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212863610 CMS
Viatris Specialty LLC $99.7405/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238484651 CMS
Viatris Specialty LLC $160.9005/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238484653 CMS
Viatris Specialty LLC $57.5105/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238484657 CMS
Viatris Specialty LLC $4,410.3805/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238484663 CMS
Viatris Specialty LLC $202.6705/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238484665 CMS
Viatris Specialty LLC $714.3605/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238484707 CMS
Regeneron Healthcare Solutions, Inc. $4,908.0005/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212863604 CMS
Regeneron Healthcare Solutions, Inc. $265.0705/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212863606 CMS
Regeneron Healthcare Solutions, Inc. $361.7305/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212863600 CMS
Regeneron Healthcare Solutions, Inc. $111.1805/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212863602 CMS
GlaxoSmithKline, LLC. $4,062.5005/01/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1191636918 CMS
GENZYME CORPORATION $138.8704/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233242561 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $312,059.12 348
PY2020 $162,651.67 116
PY2021 $104,541.28 84
PY2022 $183,927.50 173
PY2023 $282,861.59 294
PY2024 $348,690.08 257
PY2025 $430,077.81 279

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,500.00 13
PY2024 Principal investigator $1,000.00 1
PY2023 Principal investigator $18,114.90 5
PY2022 Recipient $1,113.60 2
PY2021 Recipient $1,603.58 1
PY2019 Recipient $1,651.00 1
PY2019 Principal investigator $650.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

13 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient GENZYME CORPORATION $250.00 11/07/2025 Covered Recipient Physician Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy No dispute reported 06/30/2026 1226089905
Recipient GENZYME CORPORATION $500.00 11/07/2025 Covered Recipient Physician Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy No dispute reported 06/30/2026 1226089946
Recipient GENZYME CORPORATION $250.00 10/22/2025 Covered Recipient Physician Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy No dispute reported 06/30/2026 1226089953
Recipient GENZYME CORPORATION $250.00 10/04/2025 Covered Recipient Physician Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy No dispute reported 06/30/2026 1226089928
Recipient GENZYME CORPORATION $500.00 09/30/2025 Covered Recipient Physician Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy No dispute reported 06/30/2026 1226089934
Recipient GENZYME CORPORATION $250.00 09/26/2025 Covered Recipient Physician Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy No dispute reported 06/30/2026 1226089900
Recipient GENZYME CORPORATION $500.00 09/23/2025 Covered Recipient Physician Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy No dispute reported 06/30/2026 1226089915
Recipient GENZYME CORPORATION $250.00 06/26/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1226089896
Recipient GENZYME CORPORATION $500.00 06/13/2025 Covered Recipient Physician Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy No dispute reported 06/30/2026 1226089889
Recipient GENZYME CORPORATION $250.00 06/12/2025 Covered Recipient Physician Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy No dispute reported 06/30/2026 1226089910
Recipient GENZYME CORPORATION $250.00 05/18/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1226089921
Recipient GENZYME CORPORATION $250.00 05/18/2025 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1226089941
Recipient GENZYME CORPORATION $500.00 05/18/2025 Covered Recipient Physician Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy No dispute reported 06/30/2026 1226089959